Clinical Trials
11
Active:0
Completed:6
Trial Phases
2 Phases
Phase 1:3
Phase 2:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 2
6 (66.7%)Phase 1
3 (33.3%)Trial of NanoPac Intratumoral Injection in Lung Cancer
Phase 2
Completed
- Conditions
- Neoplasm of LungLung CancerLung Cancer, Nonsmall CellLung Cancer, Small Cell
- Interventions
- Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- NanOlogy, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT04314895
- Locations
- 🇺🇸
University of Florida Health, Gainesville, Florida, United States
🇺🇸Parkview Research Institute, Fort Wayne, Indiana, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
Phase 1
Withdrawn
- Conditions
- Kidney CancerAdenocarcinoma of KidneyAdenocarcinoma, RenalRenal Cell CarcinomaRenal Cell Cancer
- Interventions
- Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- NanOlogy, LLC
- Registration Number
- NCT04260360
Trial of NanoPac Focal Therapy for Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate CancerProstate AdenocarcinomaProstatic NeoplasmUrogenital NeoplasmsGenital Neoplasms, MaleProstate Cancer AdenocarcinomaLocalized Cancer
- Interventions
- Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- NanOlogy, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04221828
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Expanded Access to NanoDoce
- Conditions
- Urogenital Neoplasms
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- NanOlogy, LLC
- Registration Number
- NCT04060628
Expanded Access to NanoPac
- Conditions
- Locally Advanced Pancreatic CarcinomaProstate CancerLung Cancer
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- NanOlogy, LLC
- Registration Number
- NCT03756311
- Prev
- 1
- 2
- 3
- Next
News
No news found